Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) (SCIGG-124)

Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) is designed to be expressed as two chains, each chain has the same units with their parental IgG antibodies, anti-CD55 and anti-HLA-A IgGs. The two chains form heterodimer via Fc KIH technology. This BsAb can recruit complements to tumor cells. It is designed for the research of Renal cell cancer (RCC); Solid tumors therapy.

Datasheet INQUIRY

Specifications

Targets

CD55 & HLA-A

Type

Single chain IgGs

Species Reactivity

Human

Application

FuncS; Promising therapeutic agent

Related Disease

Renal cell cancer (RCC); Solid tumors

Targets

Target 1

CD55

Gene ID

1604

UniProt ID

P08174

Alternative Names

CD55; CD55 molecule, decay accelerating factor for complement (Cromer blood group); CR; TC; DAF; CROM; complement decay-accelerating factor; CD55 antigen

Target 2

HLA-A

Gene ID

3105

UniProt ID

P30443

Alternative Names

HLA-A; major histocompatibility complex, class I, A; HLAA; HLA class I histocompatibility antigen, A-1 alpha chain; antigen presenting molecule; leukocyte antigen class I-A; MHC class I antigen HLA-A heavy chain

Our products and services are for research use only, and not for use in diagnostic or therapeutic procedures.

Online Inquiry

Customer Reviews and Q&As

There are currently no customer reviews or questions for Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) (SCIGG-124). Click the button below to contact us or submit your feedback about this product.

Recombinant Anti-CD55 x Anti-HLA-A Bispecific Antibody (scIgG) (CAT#: SCIGG-124)

Specifications

Targets

Customer Reviews and Q&As